As hepatocellular carcinoma (HCC) is one of the most common tumors worldwide, development of novel therapeutic approaches for HCC is urgently needed. Two different genes, LETM1 and CTMP, which target mitochondrial functions, were chosen and linked using 2A-peptide sequence. Successful self-cleavage of 2A-peptide induced synergistic antitumor effect in the liver of H-ras12V, the HCC model mice, by simultaneous activation of LETM1 (Leucine zipper/EF hand-containing transmembrane-1) and CTMP (carboxylterminal modulator protein). Overexpression of LETM1 and CTMP significantly reduced the incidence of tumorigenesis, which were confirmed by gross and microscopic observations. Morphological changes in mitochondria, such as swelling and loss of cristae, were significant, and the prolonged activation of defects in mitochondrial function led to mitochondria-mediated apoptosis. Furthermore, with CTMP as a direct binding partner of Akt1, and LETM1 as a binding partner of CTMP, LETM1-2A-CTMP downregulated the Akt1 pathway at both Ser473 and Thr308 sites of phosphorylation. Proliferation and angiogenesis, which are important in cancer prognosis, were reduced in tumor sites after introduction of LETM1-2A-CTMP. Taken together, the results indicate that introduction of the mitochondria-targeting genes, LETM1 and CTMP, and self-processing capacity of 2A-peptide sequence exerts an antitumor effect in liver of H-ras12V mice, suggesting its potential as a tool for gene therapy.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer and the fifth most common malignancy worldwide. 1 HCC is often diagnosed at an advanced stage when it is no longer susceptible to curative therapies. Highly active drugmetabolizing pathways and multidrug resistance transporter proteins in tumor cells further diminish the efficacy of the current therapeutic regimens for HCC. 2 Therefore, alternative approaches are needed to overcome these barriers to enhance therapeutic efficacy.
Liver is a well-suited target organ for development of alternative strategies as it is easily targeted by both viral and non-viral gene delivery systems. 3 In this regard, non-viral gene therapy vectors based on polyethylenimine are particularly promising. Overcoming the limitations of polyethylenimine as a gene carrier, galactosylated poly(ethylene glycol)-chitosan-graftspermine (GPCS) copolymer was synthesized with low cytotoxicity and optimized for hepatocyte targeting using an amide bond between galactosylated poly(ethylene glycol) and chitosan-graftspermine. 4 As not just one gene or protein is involved in tumorigenesis, multiple targeting is needed for an efficient therapeutic approach. Self-cleavage activity of 2A peptide has proved to be a powerful tool for simultaneous delivery of two or more genes. 5, 6 It coexpresses functional heterologous proteins under the control of a single promoter.
Mitochondria may be the effective target of anticancer therapy. [7] [8] [9] As mitochondria functions as a regulator of basic cellular functions, it has been implicated in various aspects of tumorigenesis. 10 The morphology of mitochondria has been emphasized in that it has intimate ties with cell physiology. 11 For example, fragmented mitochondrial morphology with disrupted cristae is correlated with apoptotic cytochrome c release, whereas tubular morphology promotes resistance to apoptotic stimuli. 12 Leucine zipper/EF hand-containing transmembrane-1 (LETM1), is a mitochondrial inner membrane protein that functions in mitochondria shaping. 13 Our previous study showed that LETM1 overexpression disrupts cristae of mitochondria, releases cytochrome c and finally induces apoptosis in lung cancer.
14 Carboxyl-terminal modulator protein (CTMP) is a binding partner of Akt and negatively regulates its function. 15 It has been detected in the mitochondria, and a recent study determined that LETM1 is associated with CTMP to modulate mitochondrial morphology via OPA1 cleavage. 16 Here, we attempted to link LETM1 and CTMP using 2A-peptide sequence and proved its synergistic therapeutic efficacy in liver of H-ras12V, HCC model mice. Swollen mitochondria with disrupted cristae displayed increased Bax and cytochrome c release, and induced apoptosis. These data implicate the 2A-peptide sequence as a powerful candidate to target two or more genes for therapeutic use, and both LETM1 and CTMP as putative candidates for mitochondria-controlling target molecules. 1 
MATERIALS AND METHODS Materials
Antibodies against phospho-Akt1 at Thr308, phospho-Akt1 at Ser473, AMPK (AMP kinase), Bax, cytochrome c, b-actin, PCNA (proliferating cell nuclear antigen), VEGF (vascular endothelial growth factor) and FGF-2 (fibroblast growth factor-2) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal antibody against CTMP was produced using a general method described elsewhere. [17] [18] [19] Anti-Apaf-1 was obtained from Abcam (Beverly, MA, USA) and anti-LETM1 from Abnova (Taipei, Taiwan). Phospho-AMPK at Thr172 was purchased from Cell Signaling Technology (Boston, MA, USA). In situ Cell Death Detection Kit was obtained from Roche Applied Science (Indianapolis, IN, USA). GPCS was synthesized as previously described. 4 
Animals
Breeding pairs of H-ras12V liver cancer model mice were obtained from Korea Research Institute of Bioscience and Biotechnology (Daejon, Korea) and maintained in a laboratory animal facility with temperature and relative humidity maintained at 23 ± 2 1C and 50 ± 20%, respectively, under a 12-hour light/dark cycle. H-ras12V liver cancer model has been established as previously described, 20 and treatment started from the age of 20 weeks when the animals starts to develop HCC.
Twenty-week-old mice were randomly divided into five groups (n ¼ 5 per group). Three expression plasmids containing LETM1, CTMP and LETM1-2A-CTMP were complexed with GPCS and introduced to livers of the mice via tail vein injection. After eight injections (twice a week), mice were sacrificed and livers were analyzed to evaluate the therapeutic efficacy of LETM1-2A-CTMP.
Injection of GPCS/LETM1-2A-CTMP
Fifty micrograms of pLETM1-2A-CTMP were prepared in 100 ml distilled water and an appropriate amount of GPCS at a N/P ratio of 20 in same volume. By gentle vortexing, complex of GPCS with pLETM1-2A-CTMP was formed and after 30 min of incubation, complex was injected into each H-ras12V mouse through the tail vein. After eight times of injection within 4 weeks, mice were sacrificed and collected samples were analyzed. All experimental protocols were reviewed and approved by the Animal Care and Use Committee of Seoul National University (SNU-110628-1).
Electron microscopy
Livers were fixed in modified Karnovsky's fixative before post-fixation in 1% osmium tetroxide in 0.05 M sodium cacodylate buffer (pH 7.2). Uranyl acetate (0.5%) was used for en bloc staining. The livers were dehydrated in an ethanol series and embedded in Spurr's resin. Ultrathin sections were stained with 2% uranyl acetate and Reynolds' lead citrate, and observed by transmission electron microscopy using an LIBRA 120 apparatus (Carl Zeiss, Oberkochen, Germany).
Western blot analysis
Livers were homogenized and protein concentrations were measured with a Bradford kit (Bio-Rad, Hercules, CA, USA). An equal amount of protein (30 mg) was loaded onto an sodium dodecyl sulfate-containing gel and separated. Primary and secondary antibodies conjugated with horseradish peroxidase (Invitrogen, Carlsbad, CA, USA) were applied according to the manufacturer's protocols. Bands of interest were obtained with an LAS-3000 luminescent image analyzer (Fujifilm, Tokyo, Japan).
Histopathological examination and immunohistochemistry (IHC)
Liver sections were prepared at a thickness of 3 mm on charged slide glasses (Fisher Scientific, Pittsburgh, PA, USA). Slides were stained with hematoxylin and eosin for histopathological analysis. Sections were deparaffinized, rehydrated, antigens were retrieved and endogenous peroxidase was quenched for immunohistochemistry. Primary and secondary antibodies and 3,3'-diaminobenzidine were applied accordingly (Vector Laboratories, Burlingame, CA, USA). Slides were reviewed using a light microscope (Carl Zeiss, Thornwood, NY, USA). Staining intensity was assessed by counting the number of positive cells in randomly selected fields viewed with appropriate magnification using In Studio version 3.01 (Pixera, San Jose, CA, USA).
Terminal transferase-biotin dUTP nick end labeling (TUNEL) assay
Sections were stained by in situ Cell Death Detection Kit after deparaffinized by xylene, ethanol and then antigens were retrieved in 0.1 M citrate buffer (pH 6.0). Sections were then incubated in a humidified chamber at 37 1C for 1 h with TUNEL assay mixture containing TdT enzyme (TdT enzyme mediated digoxigenin-dUTP). Slides were washed with phosphate buffered saline, incubated with converter-AP in humidified chamber for 30 min at room temperature and washed again. Another incubation with NBT/BCIP as a substrate for 10 min in dark, purple color was developed and examined under microscopy.
Statistical analysis
Quantification of Western blot analyses was performed with Multi-Gauge version 2.02 program (Fujifilm). All data are given as mean ± s.e., and significant differences between groups were determined by unpaired t-test (Graphpad Software, San Diego, CA, USA).
RESULTS

LETM1-2A-CTMP overexpresses both LETM1 and CTMP in vivo
LETM1 and CTMP were linked with 2A-peptide, and finally subcloned into CMV-eGFP vector ( Figure 1a) . Delivery efficiency and expression of LETM1 and CTMP in livers of H-ras12V mice were evaluated by Western blot using whole lysates ( Figure 1b ). As proved in previous studies, 14, 17, 19 LETM1-treated mice showed increase in LETM1, and CTMP-treated mice showed increase in CTMP. Confirming the successful cleavage of 2A-peptide linking LETM1 and CTMP, mice treated with LETM1-2A-CTMP showed increase in both LETM1 and CTMP (Figures 1c and d) .
LEMT1-2A-CTMP significantly slows progression of liver cancer in H-ras12V mice In gross morphology, 24-week-old H-ras12V mice showed varioussized tumors on the surface of the liver. When therapeutic genes were introduced to the animals, both the size and number of tumor nodules were markedly reduced ( Figure 2 Histopathologically, lesions were graded into altered foci (welldemarcated foci with minimal cytological changes), hepatocellular adenomas (benign neoplasmic lesions where hepatocytes proliferate with numerous thin-walled vessels, without portal tracts) and hepatocellular adenocarcinomas (malignant neoplasmic lesions with well-differentiated larger hepatocytes, frequently with polymorphic nucleus and mitotic figures). In nontreated groups, control and vector control, malignant signs of hepatocellular adenocarcinoma, such as mitotic figures, were shown. CTMP-, LETM1-and LETM1-2A-CTMP-treated mice remained in benign state, with hepatocellular adenoma and altered foci (Table 1) .
LETM1-2A-CTMP shows antitumor effect via mitochondria-mediated apoptosis LETM1 is located in inner mitochondrial membrane. We previously reported a role of CTMP in mitochondria-mediated apoptosis. 14 Appropriately, the morphology of mitochondria was presently observed using transmission electron microscopy. Introduction of LETM1 and CTMP induced swelling of mitochondria and disruption of cristae, but the morphology of nucleus remained intact. However, proving that LETM1-2A-CTMP synergistically induces more cell death in tumors, nuclei in LETM1-2A-CTMP-treated mice began to show apoptotic signs. Nuclear fragmentation, condensed chromatin lining and indentations of the nuclear membrane were observed with mitochondria defects (Figure 3a) . Apaf-1, Bax and cytochrome c were screened as representatives of mitochondria-mediated apoptosis by Western blot. These apoptosis-related proteins were increased following treatment with LETM1 and CTMP. LETM1-2A-CTMP further induced mitochondria-mediated apoptosis and a significant increase in apoptosis-related proteins was observed (Figures 3b and c) . TUNEL assay indicated significant apoptotic cells in LETM1-and CTMP-treated groups, and still more in LETM1-2A-CTMP-treated group (Figure 3d) . TUNELpositive cells were counted at five different fields of each slide and statistical analysis confirmed the results with high significance (Figure 3e ).
LETM1-2A-CTMP produces antitumor effect via downregulation of Akt1 CTMP was initially identified as a cytosolic interactor of Akt1. Western blot analyses were performed to examine the levels of CTMP, as a binding partner of Akt1, and AMPK, as a negative regulator of Akt1. The total AMPK level remained the same even after the introduction of LETM1, CTMP and LETM1-2A-CTMP. However, phosphorylated AMPK at Thr172 showed a very significant increase in LETM1 and LETM1-2A-CTMP (Figures 4a  and b) . Total Akt1 did not change, but phosphorylation of Akt1 at Ser473 and Thr308 decreased accordingly (Figure 4c ). After statistical analysis, the effect of LETM1-2A-CTMP in Akt1 phosphorylation proved to be significant (Figure 4d ). LETM1-2A-CTMP reduces cell proliferation in H-ras12V liver cancer model mice PCNA is expressed in the nuclei of cells during DNA synthesis phase of the cell cycle. To investigate the capacity of cancer cell proliferation, PCNA protein level was determined with Western blot using whole lysate. LETM1-2A-CTMP produced significant inhibition of proliferation compared to LETM1 or CTMP alone (Figures 5a and b) . The level of PCNA protein was further examined with immunohistochemistry; a decreasing pattern of PCNA-positive cells was detected. PCNA-positive cells were counted at five different fields of each slide and statistical analysis confirmed the significant synergistic antitumor effect (Figures 5c and d) .
LEMT1-2A-CTMP reduces angiogenesis in H-ras12V liver cancer model mice Neovasculization is one of the main characteristics of tumorigenesis. VEGF is a signal protein produced by cells. VEGF stimulates vasculogenesis and angiogenesis. VEGF of LETM1-2A-CTMP-treated group was significantly decreased compared to control and vector control. FGF-2 is present in the subendothelial extracellular matrix of blood vessels and is activated in tumor development. FGF-2, as a potent angiogenic growth factor, was decreased significantly in LETM1-2A-CTMP-treated mice (Figures 6a and b) . Immunohistopathological staining confirmed the decreasing VEGF ( Figure 6c ) and FGF-2 ( Figure 6d ) in margins of normal to tumor areas of each group.
DISCUSSION
The use of self-cleavage 2A peptide sequence to express multiple proteins with single promoter is a promising area in biology research. 6 However, the use of 2A peptide has been limited to the field of generating transgenic animals, especially pigs, in that it makes multiple genes to express through a single round of nuclear transfer. 21, 22 Here, we attempted to exploit the selfcleavage potential of 2A peptide sequence to target two different genes, LETM1 and CTMP, in the treatment of HCC. Even though ras activation is not common in human HCC, activated mutations in ras have been found in all human tumors, and the frequency of ras mutations was the highest among the genes that are associated with cancers. 23 Murine HCCs also express H-ras, which is activated in 70% of cases, supporting the view that H-ras has a key role in hepatocarcinogenesis.
Use of two independent transcriptional units to express two different genes may create an imbalance of expression levels according to the order inside the expression vector. 24, 25 However, when designing an expression vector using the 2A peptide sequence, the order of the target genes does not need to be taken into consideration. As it shares single promoter and cleavage occurs at the end of 2A peptide, the genes should be expressed in independent manners once cleaved successfully. 6 Delivery and cleavage efficiency of 2A peptide was confirmed with Western blot (Figure 1b) and following statistical analysis (Figure 1c) . The lack of a shift in protein size for both LETM1 and H-ras12V model starts to develop HCC from the age of 20 weeks. In H-ras12V mice, tumor nodules can be observed on the surface of the livers, H-ras12V gene can be detected in genomic DNA and H-ras protein expresses in the margin of normal and tumor region (Supplementary Figure 2) . Efficacy evaluation of 2A peptide in livers of H-ras12V HCC model mice revealed the decrease of prominent nodules on the surface of the organ (Figure 2 ). Histopathological analysis confirmed that introduction of therapeutic genes (LETM1, CTMP and LETM1-2A-CTMP) slowed down the progression of altered foci to hepatocellular adenocarcinoma (Table 1) . LETM1 and CTMP alone have shown therapeutic effects in lungs of K-ras LA1 , lung cancer model mice in our previous studies. 14, 17, 19 Moreover, the present data gained from the HCC model support the possibility of LETM1 and CTMP as the therapeutic candidates.
The mitochondrion is a central component of cellular maintenance, and many studies have been focused on exploring its mechanisms related to diseases that are directly related to energy metabolism, such as Parkinson's disease 26, 27 and various cancers. 10, [28] [29] [30] As both LETM1 and CTMP have been reported to participate in maintaining the morphology of mitochondria, 13, 31 overexpression of both was expected to bring mitochondrial defects capable of inducing cancer cell death. Under normal progress towards HCC, mitochondria should show a tubular morphology, which promotes resistance to apoptotic stimuli. (Figure 3b ). Bax is a proapoptotic protein that induces cell death by acting on mitochondria. 32, 33 Cytochrome c binds to Apaf-1 and triggers activation of caspase-3-dependent apoptosis pathway. 34, 35 Changes in cleaved caspase-8 was minor, confirming that the phenomenon of mitochondria-dependent apoptosis is prominent ( Supplementary  Figure 3) . When cross-confirmed with TUNEL assay for DNA fragmentation, TUNEL-positive cells were increased significantly in the LETM1-2A-CTMP-treated group (Figures 3c and d) .
When cells are under stress of growth and biosynthetic synthesis suppression, such as exposure of cancer cells to therapeutic agents, AMPK is activated accordingly. 36 In this study, introduction of LETM1, CTMP and LETM1-2A-CTMP phosphorylated AMPK at Thr172, leading to the activation of the energy sensor AMPK (Figures 4a and b) . Interestingly, mice treated solely with CTMP showed lesser increase in AMPK phosphorylation due to the indirect connection with mitochondria and phosphoinositol-3-kinase (PI3K)-Akt1. One report described that activation of AMPK in HCC is capable of suppressing cancer cell growth, 37 which supports the present idea that activation of AMPK phosphorylation induced HCC regression. Constitutive activation of PI3K-Akt1 signaling has been reported in many cancers including glioblastoma, advanced prostate cancer 38 and HCC. 39 Phosphorylation of Akt1 both at Ser473 and Thr308 decreased when exposed to LETM1, CTMP and LETM1-2A-CTMP (Figures 4c  and d) , satisfying the notion that LETM1, CTMP and LETM1-2A-CTMP led to mitochondrial disruption followed by apoptosis by suppressing the Akt1 pathway. Important factors to consider in evaluating the therapeutic efficacy of tumorigenesis are the proliferative and angiogenic capabilities of tumor cells. PCNA has been reported as a highly sensitive marker for cell proliferation. 40 Total homogenates of livers showed decrease in PCNA. Moreover, from the tumor sites proliferating cells were significantly reduced with the welldemarcated fibrotic margin (Figures 5a and b) . VEGF is a potent endothelial cell mitogen and key regulator of both physiologic and pathologic angiogenesis. 41, 42 FGF-2 is an important stimulator of angiogenesis that has been implicated in neoplastic progression and which is a potent mitogen for different cell types, including vascular endothelial cells and fibroblasts. 43 Attempts to neutralize or modulate FGF-2 have met with some success in controlling neovascularity and tumor growth. 44 As both VEGF and FGF-2 were decreased in mice treated with LETM1, CTMP and LETM1-2A-CTMP, with the decrease being more pronounced for the 2A peptide form, the synergistic effect of dual gene targeting with 2A peptide is confirmed ( Figure 6 ).
In summary, our results clearly demonstrate the dual targeting of LETM1 and CTMP using 2A peptides in H-ras12V HCC model mice. Successful cleavage of 2A peptide sequence induced a synergistic antitumor effect by disrupting mitochondrial morphology and leading to mitochondria-mediated apoptosis via activation of the AMPK and Akt1 pathways. Furthermore, proliferative and angiogenic capability of tumor cells decreased as a final output of the therapeutic effects. Here, we ultimately suggest that application of 2A peptide sequence in vivo to target two or more genes and selection of multiple genes targeting mitochondria for cancer therapy are promising approaches towards the development of cancer therapeutics.
